AB Science announces that masitinib study in primary and secondary progressive forms of multiple sclerosis has passed its non-futility test at 2 years The study has completed patient recruitment ...
More than 20 years ago, as Jennifer Digmann focused on completing her coursework and graduating from college, she began experiencing numbness in her hands and feet and eventually double vision. After ...
The role of imaging in diagnosing progressive multiple sclerosis (MS) and in assessing prognosis is the subject of a new review. MRI is central in the diagnostic workup of patients suspected of having ...
EXTON, Pa., June 26, 2018 /PRNewswire/ -- Largely fueled by Genentech's Ocrevus availability, a paradigm shift has occurred in the US multiple sclerosis (MS) market resulting in increased rates of ...
Symptoms come and go in most cases of multiple sclerosis (MS), a chronic disease in which the immune system attacks myelin, the nonconductive sheath that surrounds neurons' axons. Yet 10 to 15 percent ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) approved OCREVUS™ ...
Benign multiple sclerosis (MS) refers to a type of MS where someone has MS for over 15 years without developing severe disability. However, benign MS may change to a progressive form of MS. Multiple ...
Most new treatments for multiple sclerosis are for patients with the relapsing–remitting form of the disease. Those with the more advanced, progressive type are being left behind. When neurologist ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback